Journal
CURRENT HIV/AIDS REPORTS
Volume 12, Issue 3, Pages 305-312Publisher
SPRINGER
DOI: 10.1007/s11904-015-0273-9
Keywords
HIV; Statins; Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors; Cardiovascular disease; Inflammation; Immune activation
Categories
Funding
- National Institute of Child Health and Development at the National Institutes of Health [K23 HD069199, R01 NR012642, HD070490]
Ask authors/readers for more resources
HIV-infected individuals are at an increased risk of cardiovascular disease (CVD) and other HIV-related co-morbidities. This is due in part to dyslipidemia associated with antiretroviral therapy and increased inflammation and immune activation from chronic HIV infection. Statins not only have potent lipid-lowering properties but are also anti-inflammatory and immunomodulators. Studies suggest that statin therapy in the HIV-infected population may decrease the risk of CVD and other non-AIDS-defining co-morbidities. This review summarizes the recent literature on statin use in the HIV setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
